Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22363297 | 0.86 | LOX (0.45) | LOXLOXL2KCNB1AAK1ACACB | |
| SCHEMBL24925813 | 0.84 | ABCB11 (0.50) | LOXLOXL2KCNB1AAK1ACACB | |
| SCHEMBL18707542 | 0.84 | LOX (0.49) | LOXLOXL2KCNB1AAK1ACACB | |
| SCHEMBL22299306 | 0.82 | LOX (0.41) | LOXLOXL2KCNB1HPGDAAK1 | |
| SCHEMBL31421700 | 0.81 | LOX (0.48) | LOXLOXL2KCNB1ALDH1A1HPGD | |
| SCHEMBL84460 | 0.81 | LOX (0.48) | LOXLOXL2KCNB1ALDH1A1HPGD | |
| SCHEMBL12093566 | 0.79 | LOX (0.47) | LOXLOXL2KCNB1AAK1ACACB | |
| SCHEMBL20259848 | 0.78 | LOX (0.44) | LOXLOXL2KCNB1AAK1ACACB | |
| SCHEMBL23376903 | 0.78 | ALDH1A1 (0.41) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL22369466 | 0.78 | LOX (0.50) | LOXLOXL2KCNB1AAK1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | LOX 1594/4885LOXL2 2483/4885KCNB1 2707/4885 |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | CYP3A5, CYP3A43, CYP3A4 | LOX 3596/4885LOXL2 3844/4885KCNB1 275/4885 |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | LOX 268/4885LOXL2 970/4885KCNB1 258/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | LOX 268/4885LOXL2 970/4885KCNB1 258/4885 |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | LOX 4110/4885LOXL2 3731/4885KCNB1 3772/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | LOX 3332/4885LOXL2 1278/4885KCNB1 4559/4885 |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | CYP3A5, CYP3A43, CYP3A4 | LOX 3596/4885LOXL2 3844/4885KCNB1 275/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | LOX 3476/4885LOXL2 3346/4885KCNB1 4664/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | LOX 3433/4885LOXL2 3361/4885KCNB1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.